BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: Trametinib has demonstrated clinical activity as single‐agent in patients with BRAFV600E/K‐mutated unresectable or metastatic melanoma,4, 5 as well as in combination with the BRAF inhibitor dabrafenib in patients with unresectable or metastatic, BRAFV600‐mutated melanoma, either as first‐line treatment of BRAF inhibitor–naive patients6, 7, 8, 9 or as adjuvant therapy,10 in patients with metastatic BRAFV600E‐mutated non–small‐cell lung cancer,11, 12, 13 and in patients with locally advanced or metastatic BRAFV600E‐mutated anaplastic thyroid cancer.14